• Denis A Poddubnyy, In-Ho Song, and Joachim Sieper.
• Charité - Campus Benjamin Franklin, Rheumatology, Medical Department I, Hindenburgdamm 30, 12200 Berlin, Germany.
• Expert Opin Drug Saf. 2008 Jul 1;7(4):401-9.

BackgroundNonsteroidal anti-inflammatory drugs (NSAIDs) play a crucial role in the treatment of ankylosing spondylitis (AS). Most of the AS patients require a continuous and long-term NSAIDs therapy; therefore the question of NSAIDs safety in this population becomes very important.Objectiveto review the safety of celecoxib in ankylosing spondylitis treatment.MethodsThe PubMed database was searched using the keywords 'ankylosing spondylitis' and 'celecoxib', with the following extraction of clinical trials investigating efficacy and safety of celecoxib in AS.Results/ConclusionsFour clinical trials were found: three randomized controlled trials (RCTs) and one open-label extension of a previous RCT. All RCTs showed a good safety profile for celecoxib treatment in AS, similar to that of nonselective NSAIDs. However, long-term (>or= 1 year) celecoxib safety in AS was not investigated in RCTs. Based on the results of long-term non-AS celecoxib studies, most of the AS patients (because of young age and fewer comorbidities) are probably at low risk for cardiovascular and gastrointestinal complications. Celecoxib showed a good efficacy and safety profile in AS, but further investigations are needed to clarify the long-term safety of celecoxib in this group of patients.

24 keywords...

hide…